Sanarus Medical offers a range of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas, Cassi II rotational core biopsy system for automated hand-held breast biopsy, and ImarC tissue marker system for breast tissue markers visible under imaging modalities. Founded in 1999, Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system, the Visica 2TM Treatment System, which is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors, and Sanarus is sponsoring the FROST Clinical Study for early-stage breast cancer that does not involve surgical resection. Sanarus is dedicated to spreading awareness of cryoablation as a treatment option throughout the community and major breast cancer organizations throughout the country, with the goal of making it available to patients seeking an alternative to surgery.